Pay-For-Delay Ban Heads To Full Senate
A bill designed to cut prescription drug costs by forcing pharmaceutical companies to show that any so-called pay-for-delay patent settlements are not anti-competitive narrowly advanced Thursday to the full U.S. Senate....To view the full article, register now.
Already a subscriber? Click here to view full article